Tinea Infections

1. Clinical Overview

Summary

Tinea infections (dermatophytosis) are superficial fungal infections of keratinised tissues (skin, hair, nails) caused by dermatophyte fungi. These organisms exclusively colonize non-viable keratinized structures and rarely invade living tissue in immunocompetent hosts. Dermatophytoses are among the most common infectious diseases worldwide, affecting approximately 20-25% of the global population. [1,2]

Tinea infections are classified anatomically by the site of involvement: Tinea corporis (body), Tinea pedis (foot), Tinea cruris (groin), Tinea capitis (scalp), Tinea manuum (hand), Tinea faciei (face), Tinea barbae (beard), and Tinea unguium (onychomycosis, nails). The characteristic clinical presentation is an annular "ringworm" plaque with an active, scaly, erythematous border and central clearing, though morphology varies significantly by anatomical location and immune response. [3,4]

The three principal genera of dermatophytes are Trichophyton, Microsporum, and Epidermophyton. Trichophyton rubrum accounts for 60-80% of all dermatophyte infections globally and is the most common cause of chronic tinea pedis, tinea corporis, tinea cruris, and onychomycosis. [1,5]

Diagnosis is primarily clinical, supplemented by potassium hydroxide (KOH) microscopy demonstrating branching septate hyphae, and confirmed by fungal culture on Sabouraud's agar, which identifies the specific organism and determines antifungal susceptibility. Molecular techniques including PCR are increasingly available for rapid species identification. [6,7]

Management depends on the anatomical site and extent of infection. Localized cutaneous infections typically respond to topical allylamines (terbinafine) or azoles (clotrimazole, miconazole, ketoconazole), whereas tinea capitis, onychomycosis, extensive skin involvement, and Majocchi's granuloma require systemic antifungal therapy with oral terbinafine, itraconazole, or griseofulvin. [3,8]

Prognosis is excellent for superficial cutaneous infections with appropriate treatment. Onychomycosis has lower cure rates (60-75% with oral terbinafine) and high recurrence rates (20-50%). Complications include bacterial superinfection, permanent scarring alopecia from kerion formation, and rarely, widespread dermatophyte infection in immunocompromised patients. [9,10]

Key Facts

• Causative Organisms: Dermatophyte fungi from three genera: Trichophyton (most common, especially T. rubrum and T. mentagrophytes), Microsporum (especially M. canis), Epidermophyton (especially E. floccosum). [1,5]

• Transmission Categories:

  • "Anthropophilic: Human-to-human transmission (T. rubrum, T. tonsurans, E. floccosum) - typically cause chronic, low-grade inflammation"
  • "Zoophilic: Animal-to-human transmission (M. canis from cats/dogs, T. mentagrophytes from rodents) - usually induce intense inflammatory responses"
  • "Geophilic: Soil-acquired (M. gypseum) - rare, highly inflammatory [1,11]"

• Global Epidemiology: Tinea pedis affects 15-25% of adults globally, making it the most common fungal infection. Prevalence increases with age, male gender, communal bathing, occlusive footwear, and diabetes mellitus. [1,2]

• Tinea Capitis Characteristics: Most common cause of patchy alopecia in prepubertal children. Requires systemic (oral) antifungal therapy as topical agents cannot penetrate the hair shaft. T. tonsurans predominates in North America and UK; M. canis is common in Europe and Mediterranean regions. [8,12]

• Iatrogenic Modification: Topical corticosteroid application to undiagnosed tinea creates "Tinea Incognito"

• altered morphology with reduced scaling, diminished annular configuration, and persistent infection that spreads rapidly, complicating diagnosis. [13]

• Onychomycosis Burden: Affects 5-10% of adults, prevalence rising to 20-50% in those > 60 years. Accounts for 50% of all nail disorders. Dermatophytes cause 80-90% of toenail infections, with T. rubrum responsible for the majority. [9,10]

Clinical Pearls

"Two Feet, One Hand" Syndrome: A pathognomonic presentation of dermatophytosis where bilateral tinea pedis (both feet) coexists with unilateral tinea manuum (typically the dominant hand). The hand involvement results from auto-inoculation through scratching or touching infected feet. This pattern is virtually diagnostic of dermatophyte infection. [14]

Scrotal Sparing: Tinea cruris characteristically affects the inner thighs, inguinal folds, and may extend to the buttocks and lower abdomen, but spares the scrotum and penis. Scrotal involvement suggests alternative diagnoses: candidiasis (which prefers intertriginous areas and involves the scrotum), erythrasma (bacterial), or eczema. This clinical sign has high diagnostic specificity. [3,4]

Tinea Capitis Clinical Clue: Any prepubertal child presenting with scalp scaling, "dandruff," or patchy alopecia should be presumed to have tinea capitis until proven otherwise, as seborrheic dermatitis is rare in this age group. Posterior auricular or posterior cervical lymphadenopathy is a highly useful associated finding. [8,12]

The Active Border Principle: Dermatophytes actively grow at the peripheral advancing edge of lesions, where viable hyphae are found. The central clearing occurs because fungi deplete available keratin substrate centrally and host immune responses clear this area. When collecting samples for KOH microscopy or culture, always scrape the active scaly edge, not the cleared center. [3,6]

Kerion Recognition: Kerion is a severe inflammatory response to dermatophyte infection of the scalp, presenting as a boggy, purulent, painful mass with alopecia. It represents a type IV hypersensitivity reaction to fungal antigens, not bacterial superinfection (though secondary bacterial infection can occur). Kerion requires urgent systemic antifungal therapy ± oral corticosteroids to prevent permanent scarring alopecia. [8,12]

Majocchi's Granuloma Warning: This is a deep dermatophyte folliculitis and perifolliculitis, often occurring after topical corticosteroid misuse on tinea corporis or following shaving of infected areas. Presents as follicular papules or nodules rather than superficial scaling. Requires oral antifungal therapy as topical agents cannot penetrate sufficiently. [13,15]

---

2. Epidemiology

Global Burden and Incidence

Dermatophyte infections are among the most prevalent infectious diseases globally, with an estimated 20-25% of the world's population affected at any given time. Prevalence varies significantly by anatomical site, geographic region, climate, and demographic factors. [1,2]

Site-Specific Prevalence:

• Tinea Pedis: 15-25% of adults globally, reaching 30-70% in high-risk populations (military personnel, athletes, miners). Most common dermatophytosis in temperate climates. [1,2]
• Onychomycosis: 5-10% overall prevalence, increasing to 20-50% in adults > 60 years. Represents 50% of all nail disorders. [9,10]
• Tinea Corporis: 4-13% prevalence in tropical regions; lower in temperate zones. Common in wrestlers and athletes with close skin contact. [3,4]
• Tinea Cruris: Predominantly affects adult males (3:1 male:female ratio) due to anatomical and lifestyle factors. More common in hot, humid climates. [4]
• Tinea Capitis: Almost exclusively affects prepubertal children (peak age 3-7 years). Prevalence 3-8% in urban pediatric populations, with higher rates in African-Caribbean children due to hair structure susceptibility. [8,12]

Geographic and Species Variations

Organism Distribution varies by geography:

• Trichophyton rubrum: Dominant worldwide (60-80% of all dermatophyte infections), causing chronic, low-grade infections of skin and nails. Anthropophilic. [1,5]
• Trichophyton tonsurans: Leading cause of tinea capitis in North America, UK, and parts of Africa. [12]
• Microsporum canis: Zoophilic (cats, dogs); common in Europe, Mediterranean, Latin America. Frequent cause of tinea capitis in regions with pet exposure. [11,12]
• Trichophyton mentagrophytes: Zoophilic and anthropophilic variants; causes more inflammatory infections. [11]
• Epidermophyton floccosum: Anthropophilic; common cause of tinea cruris and pedis, does not invade hair. [1]

Emerging Resistance: Terbinafine-resistant T. rubrum and T. mentagrophytes (especially T. indotineae clade) have emerged in South Asia and are spreading globally, associated with misuse of topical corticosteroid-antifungal combinations. [5,16]

Risk Factors

Host Factors

• Age: Tinea capitis in children; onychomycosis increases with age (cumulative trauma, slower nail growth, peripheral vascular disease)
• Sex: Males > females for tinea pedis and cruris (sweating, occupational exposure, anatomy)
• Genetic predisposition: HLA-DR8/DQ4 haplotypes associated with chronic dermatophytosis; mutations in CARD9 gene predispose to deep/disseminated dermatophytosis [11]
• Immunosuppression: HIV/AIDS, diabetes mellitus, immunosuppressive medications, hematologic malignancies increase risk of extensive/refractory infections [13]
• Atopic diathesis: Reduced cutaneous immunity in atopic individuals [2]

Environmental Factors

• Climate: Warm, humid environments favor dermatophyte transmission and growth
• Occlusive footwear: Promotes moisture and maceration (tinea pedis)
• Communal bathing: Shared showers, locker rooms, swimming pools (fomite transmission)
• Close contact: Overcrowding, contact sports (wrestling), shared fomites (combs, towels, bedding) [1,2,11]

Occupational Risk

• Athletes (especially wrestlers, swimmers, runners)
• Military personnel in hot climates
• Miners, industrial workers with occlusive protective equipment
• Agricultural workers with animal contact (zoophilic species) [1,2]

---

3. Pathophysiology

Dermatophyte Biology and Taxonomy

Dermatophytes are keratinophilic fungi belonging to the order Onygenales. They possess unique enzymatic machinery enabling keratin digestion, allowing colonization of skin, hair, and nails. Unlike yeasts (Candida) or molds (Aspergillus), dermatophytes are specialized for keratinized tissue invasion. [1,11]

Three Genera:

1. Trichophyton: Invade skin, hair, and nails
2. Microsporum: Invade skin and hair (not nails)
3. Epidermophyton: Invade skin and nails (not hair)

Transmission Classification based on ecological niche:

• Anthropophilic species (T. rubrum, T. tonsurans, E. floccosum): Adapted to human hosts, transmitted person-to-person, typically cause chronic low-grade inflammation with minimal immune response
• Zoophilic species (M. canis, T. mentagrophytes var. mentagrophytes): Natural animal pathogens that can infect humans, elicit robust inflammatory responses (kerion, intense erythema)
• Geophilic species (M. gypseum): Soil-dwelling, rarely infect humans, cause highly inflammatory reactions when they do [1,11]

Infection Process

Step 1: Adherence

Arthroconidia (infectious spores) adhere to corneocytes via adhesins and mannan proteins. Adherence requires moisture and is enhanced by skin trauma (micro-abrasions from scratching, shaving, maceration). [11]

Step 2: Germination and Invasion

In appropriate conditions (warmth, moisture, keratin substrate), arthroconidia germinate into hyphae. Dermatophytes secrete multiple keratinolytic enzymes:

• Subtilisins (serine proteases)
• Metalloproteinases
• Sulfite

These enzymes digest keratin, allowing hyphal penetration into the stratum corneum, hair shaft, or nail plate. Importantly, in immunocompetent hosts, dermatophytes remain confined to non-viable keratinized structures and do not invade living epidermis or dermis. [1,11]

Step 3: Colonization and Proliferation

Hyphae grow within the stratum corneum, advancing centrifugally (outward) in search of fresh keratin substrate. Growth rate depends on:

• Keratin availability
• Host immune response
• Organism species and virulence factors [11]

Step 4: Immune Response and Inflammation

Fungal cell wall antigens (mannans, glycopeptides) penetrate into the viable epidermis and dermis, triggering:

• Innate immunity: Recognition by Toll-like receptors (TLR2, TLR4) and C-type lectin receptors (Dectin-1) on keratinocytes, Langerhans cells, and dermal dendritic cells
• Adaptive immunity: Type IV delayed hypersensitivity response mediated by Th1 cells (IFN-γ, IL-2) and Th17 cells (IL-17, IL-22)
• Clinical manifestation: Erythema, pruritus, scaling, vesiculation

The degree of inflammation correlates inversely with chronicity: zoophilic species induce intense inflammation and self-limiting infection; anthropophilic species (T. rubrum) evade robust immune responses, causing chronic low-grade infection. [11,15]

Pathogenesis of Annular Lesions ("Ringworm")

The characteristic annular morphology results from:

1. Centrifugal hyphal growth: Fungi advance outward seeking fresh keratin
2. Central keratin depletion: Exhaustion of substrate in central areas
3. Immune-mediated central clearing: Host cell-mediated immunity clears infection centrally while peripheral growth continues
4. Result: Active scaly border (viable hyphae) with central clearing (resolved infection)

This pattern is most prominent in tinea corporis and cruris; less evident in chronic plantar tinea pedis. [3,11]

Site-Specific Pathophysiology

Tinea Capitis

Hair shaft invasion occurs in anagen (growing) phase. Fungi grow down the hair follicle and invade the hair shaft via:

• Ectothrix pattern: Microsporum species; spores form on outer hair shaft surface, causing hair to fluoresce under Wood's lamp
• Endothrix pattern: Trichophyton species (T. tonsurans, T. violaceum); hyphae and spores confined within hair shaft, no fluorescence

Kerion formation represents exaggerated type IV hypersensitivity, often to zoophilic species (M. canis), with deep follicular inflammation, neutrophil infiltration, and risk of permanent scarring alopecia. [8,12]

Onychomycosis

Dermatophytes invade the nail via several routes:

• Distal-lateral subungual onychomycosis (DLSO): Most common (90%); invasion from hyponychium under distal nail plate
• Superficial white onychomycosis (SWO): Direct invasion of dorsal nail plate surface (T. mentagrophytes)
• Proximal subungual onychomycosis (PSO): Invasion via proximal nail fold; associated with immunosuppression
• Endonyx: Fungal invasion of nail plate without subungual hyperkeratosis (T. soudanense, T. violaceum)

Onychomycosis is difficult to cure because:

• Low blood supply to nail bed
• Slow nail growth (toenails: 1mm/month)
• Protected fungal niche under nail plate [9,10]

---

4. Clinical Presentation

Classification by Anatomical Site

Tinea Corporis (Body Ringworm)

Clinical Features:

• Classic morphology: Annular (ring-shaped) plaques with well-defined, raised, scaly erythematous borders and central clearing
• Distribution: Trunk, limbs, non-hair-bearing areas
• Symptom: Pruritus (variable intensity)
• Number: Single or multiple lesions; can coalesce into polycyclic patterns
• Variants:
  • "Zoophilic infection (M. canis from pets): Highly inflammatory, vesicular border, rapid spread"
  • "Tinea imbricata (T. concentricum, Pacific Islands, South America): Concentric rings of scale"
  • "Majocchi's granuloma: Follicular papules/nodules; deep infection after topical corticosteroid use or shaving [3,4,13,15]"

Differential Diagnosis: Pityriasis rosea, nummular eczema, psoriasis, granuloma annulare, erythema migrans (Lyme disease)

Tinea Pedis (Athlete's Foot)

Most common fungal infection globally. Three clinical presentations:

1. Interdigital Type (most common):

• Maceration, fissuring, scaling between toes (typically 4th/5th web spaces)
• Malodor common (secondary bacterial overgrowth)
• Entry point for bacterial cellulitis (recurrent leg cellulitis often originates from chronic tinea pedis) [1,2,17]

2. Moccasin Type (Chronic Hyperkeratotic):

• Diffuse dry scaling of soles, heels, and lateral foot borders (distribution resembles a moccasin)
• "Two feet, one hand syndrome" often present
• Minimal inflammation; chronic, indolent course
• Almost always caused by T. rubrum [1,2]

3. Vesiculobullous Type:

• Acute vesicles or bullae on instep and mid-plantar foot
• Intensely pruritic
• Often zoophilic species (T. mentagrophytes)
• May trigger "id reaction" (dermatophytid) - widespread vesicular eruption on hands/body [2,14]

Differential Diagnosis: Contact dermatitis, pompholyx eczema, psoriasis, bacterial infection

Tinea Cruris (Jock Itch)

Clinical Features:

• Well-demarcated, erythematous plaques with raised scaly borders on medial thighs, inguinal folds
• Pathognomonic sign: Spares scrotum and penis (if scrotum involved, consider candidiasis, erythrasma, or eczema)
• Extends peripherally onto thighs, buttocks, lower abdomen
• More common in males (3:1), especially in hot/humid climates, obesity
• Pruritus prominent [3,4]

Differential Diagnosis: Candidiasis (involves scrotum), erythrasma (coral-red fluorescence under Wood's lamp), inverse psoriasis, seborrheic dermatitis

Tinea Capitis (Scalp Ringworm)

Almost exclusively affects prepubertal children (protective sebum after puberty inhibits dermatophyte growth). Four clinical patterns:

1. Grey Patch Type:

• Scaly patches with alopecia
• Broken-off hairs at 2-3mm ("exclamation mark hairs")
• Minimal inflammation
• Microsporum species [8,12]

2. Black Dot Type:

• Hair breaks at scalp surface leaving black dots (broken hair shafts within follicles)
• Trichophyton tonsurans, T. violaceum
• Endothrix pattern [8,12]

3. Kerion:

• Boggy, tender, purulent inflammatory mass
• Pustules, exudate, matted hair
• Posterior auricular/cervical lymphadenopathy
• Represents intense type IV hypersensitivity (NOT bacterial abscess)
• Risk of permanent scarring alopecia if untreated
• Usually zoophilic species (M. canis) [8,12]

4. Favus (rare):

• Chronic infection with thick crusts (scutula - cup-shaped yellowish crusts)
• Scarring alopecia
• T. schoenleinii (rare globally)

Key Clinical Sign: Posterior auricular or posterior cervical lymphadenopathy is common and helpful diagnostically. [8,12]

Differential Diagnosis: Seborrheic dermatitis (rare in children), alopecia areata, trichotillomania, bacterial folliculitis

Tinea Manuum (Hand)

Clinical Features:

• Unilateral hyperkeratotic scaling of palmar surface and fingers
• Exaggerated palmar creases filled with scale
• "Two feet, one hand syndrome" (bilateral tinea pedis + unilateral tinea manuum of dominant hand from scratching feet)
• Usually T. rubrum [3,14]

Differential Diagnosis: Psoriasis, eczema, contact dermatitis

Tinea Faciei (Face Ringworm)

Clinical Features:

• Often atypical morphology (less annular than corporis)
• Erythematous, scaly patches on face (excluding beard area)
• Can mimic rosacea, lupus erythematosus, polymorphic light eruption
• Frequently misdiagnosed and treated with topical corticosteroids → tinea incognito [3,13]

Differential Diagnosis: Rosacea, lupus erythematosus, seborrheic dermatitis, contact dermatitis

Tinea Barbae (Beard Area)

Clinical Features:

• Inflammatory follicular infection of bearded area (men)
• Deep pustular folliculitis, kerion-like presentation
• Often zoophilic (T. verrucosum from cattle in agricultural workers)
• Can cause scarring alopecia [3]

Differential Diagnosis: Bacterial folliculitis, pseudofolliculitis barbae (razor bumps)

Tinea Unguium (Onychomycosis)

Affects 5-10% of adults, 20-50% of elderly. Five clinical patterns:

1. Distal-Lateral Subungual Onychomycosis (DLSO) - 90% of cases:

• Yellow-white discoloration at distal/lateral nail edge
• Subungual hyperkeratosis (debris accumulation)
• Onycholysis (nail plate separation)
• Nail thickening, crumbling
• T. rubrum most common [9,10]

2. Superficial White Onychomycosis (SWO):

• White patches on dorsal nail plate surface
• Powdery, friable surface
• T. mentagrophytes [9,10]

3. Proximal Subungual Onychomycosis (PSO):

• White discoloration starting at proximal nail fold (cuticle area)
• Marker of immunosuppression (HIV, immunosuppressive drugs)
• T. rubrum [9,10]

4. Endonyx Onychomycosis:

• Milky-white discoloration of nail plate without subungual hyperkeratosis
• T. soudanense, T. violaceum [9,10]

5. Total Dystrophic Onychomycosis (TDO):

• End-stage of untreated DLSO or PSO
• Complete nail destruction

Clinical Impact: Pain, secondary bacterial infection, functional impairment, psychosocial distress. [9,10]

Differential Diagnosis: Psoriatic nail disease, trauma, lichen planus, onychogryphosis, bacterial paronychia

Modified Presentations

Tinea Incognito

Results from topical corticosteroid application to undiagnosed tinea. Features:

• Loss of typical annular morphology
• Reduced scale and erythema (masking)
• Paradoxical spread despite apparent improvement
• Follicular pustules, atypical patterns
• Diagnostic confusion
• Treatment: Stop corticosteroids, start appropriate antifungals [13]

Widespread Dermatophytosis

Rare; occurs in immunosuppressed patients (HIV, chronic corticosteroid use, inherited CARD9 deficiency):

• Extensive cutaneous involvement
• Unusual sites (face, widespread)
• Deeper invasion (dermal granulomas)
• Requires systemic therapy [13,15]

Red Flags Requiring Urgent Assessment

1. Kerion: Risk of permanent scarring alopecia; requires urgent oral antifungals ± oral corticosteroids
2. Majocchi's granuloma: Deep infection requiring systemic therapy
3. Severe bacterial superinfection: Cellulitis, lymphangitis
4. Facial tinea in young women: May mimic lupus erythematosus; misdiagnosis can delay appropriate treatment
5. Proximal subungual onychomycosis: May indicate immunosuppression (HIV)
6. Extensive disease in immunocompromised patients: Risk of deep/disseminated infection [8,9,13,15]

---

5. Clinical Examination

Systematic Approach

History Taking

Key Questions:

• Duration: Acute (days-weeks) suggests zoophilic/highly inflammatory; chronic (months-years) suggests T. rubrum
• Symptoms: Pruritus intensity, pain (kerion, Majocchi's granuloma)
• Distribution: Single site vs. multiple (auto-inoculation)
• Contacts: Household members, pets (especially cats, dogs with patchy hair loss), farm animals
• Occupation: Athletes, military, agricultural workers, hairdressers
• Communal exposure: Gyms, pools, shared showers
• Treatments tried: Especially topical corticosteroids (tinea incognito risk)
• Immunosuppression: HIV, diabetes, corticosteroid use, chemotherapy
• Previous fungal infections: Recurrent tinea pedis common [3,4,8]

General Examination

Inspection:

• Distribution: Check all common sites - if tinea corporis present, examine feet (source); if unilateral tinea manuum, examine feet
• Morphology:
  • "Active border: Raised, scaly, erythematous, advancing edge (where viable hyphae reside)"
  • "Central clearing: Resolving infection"
  • "Pattern: Annular, polycyclic, arcuate"
• Scale: Fine vs. thick hyperkeratotic
• Inflammation: Minimal (chronic T. rubrum) vs. intense (zoophilic, kerion)
• Secondary changes: Excoriation, lichenification (chronic scratching), bacterial superinfection (crusting, pustules) [3,4]

Palpation:

• Kerion: Boggy, fluctuant (not a true abscess; do not incise)
• Lymphadenopathy: Posterior auricular, cervical (tinea capitis)

Site-Specific Examination

Tinea Capitis:

• Scalp scaling, broken hairs, patches of alopecia
• Black dots (broken hairs at scalp surface)
• Cervical/posterior auricular lymph nodes
• Examine family members and pets [8,12]

Tinea Pedis:

• Interdigital maceration, fissures (4th-5th web spaces)
• Plantar scaling, hyperkeratosis (moccasin pattern)
• Check hands (one hand involvement suggests dermatophytid)
• Inspect for entry points for cellulitis [1,2]

Tinea Cruris:

• Bilateral symmetrical groin plaques
• Scrotal sparing (key diagnostic feature)
• Extension onto medial thighs, buttocks [4]

Nails:

• Discoloration (yellow-white)
• Subungual hyperkeratosis
• Onycholysis
• Dystrophy
• Number of nails involved (affects treatment duration) [9,10]

Diagnostic Adjuncts

Wood's Lamp Examination (UV Light, 365nm)

• Limited utility in modern practice
• Positive fluorescence: Bright green - Microsporum canis, M. audouinii (ectothrix infections)
• No fluorescence: Trichophyton species (most common organisms)
• Use: May help in tinea capitis screening in endemic areas, but negative test does not exclude tinea [8,12]

Dermoscopy

Increasingly used in clinical practice:

Tinea Corporis:

• Peripheral scaling
• Branching linear vessels

Tinea Capitis:

• "Comma hairs" (short, curved broken hairs)
• "Corkscrew hairs" (bent/twisted)
• Broken hairs with white sleeve (fungal spore cuffs)
• Black dots [8,12]

Onychomycosis:

• Longitudinal striae
• Jagged proximal edge
• Subungual hyperkeratosis [10]

---

6. Investigations

Specimen Collection Technique

Principle: Sample the active infection site where viable hyphae are present.

Skin Scrapings

Procedure:

1. Clean area with alcohol swab (remove surface contaminants)
2. Scrape the active scaly edge (advancing border) with sterile scalpel blade (No. 15) or blunt edge of slide
3. Collect scales onto black paper or directly into sterile container
4. Sample size: At least 1-2mm² of scales [3,6,7]

Avoid: Cleared center (few viable hyphae)

Hair and Scalp Samples

Procedure:

1. Pluck 10-15 hairs with visible involvement (broken hairs, fluorescent hairs under Wood's lamp) using forceps - include roots
2. Scrape associated scale from scalp surface
3. Toothbrush technique (children): Rub sterile toothbrush over affected area; inoculate brush onto culture medium [8,12]

Nail Samples

Procedure:

1. Clean nail with alcohol
2. Clip affected distal nail (if onycholysis present)
3. Scrape subungal debris from underside of nail plate and nail bed (highest yield)
4. Drill/burr nail surface if superficial white onychomycosis
5. Send nail clippings + subungual debris [9,10]

Note: Distal nail clippings alone have low sensitivity; subungual debris is essential.

Laboratory Analysis

Direct Microscopy (KOH Preparation)

Method:

• Specimen placed on glass slide
• 10-40% potassium hydroxide (KOH) added (dissolves keratin)
• Gentle heating accelerates keratin clearance
• Examine under light microscopy (10× and 40× magnification)

Positive Findings:

• Branching septate hyphae (filaments with cross-walls)
• Arthroconidia (chains of spores)

Advantages:

• Rapid (results within hours to 24-48h)
• Cheap
• Confirms fungal infection (cannot distinguish dermatophytes from non-dermatophyte molds) [3,6,7]

Limitations:

• Operator-dependent
• 10-20% false-negative rate
• Cannot identify species
• Cannot distinguish dermatophytes from other fungi

Fungal Culture

Method:

• Specimen inoculated onto Sabouraud's dextrose agar (with antibiotics to inhibit bacteria, ± cycloheximide to inhibit non-dermatophyte molds)
• Incubated at 25-30°C for 2-4 weeks
• Colonies examined for macroscopic morphology (color, texture, topography)
• Lactophenol cotton blue mount for microscopic morphology (macroconidia, microconidia)

Results:

• Species identification (e.g., T. rubrum, M. canis, E. floccosum)
• Antifungal susceptibility testing if requested (important for refractory cases)

Advantages:

• Definitive species diagnosis
• Susceptibility testing
• High specificity [6,7]

Limitations:

• Slow (2-4 weeks)
• 30% false-negative rate (non-viable organisms, insufficient sample, overgrowth by contaminants)

Molecular Testing (PCR)

Method:

• DNA extraction from specimen
• PCR amplification of fungal DNA (ITS region, rRNA genes)
• Species identification via sequencing or probe hybridization

Advantages:

• Rapid (24-48 hours)
• High sensitivity (detects non-viable organisms)
• Species identification
• Detection of antifungal resistance genes (SQLE mutations conferring terbinafine resistance) [5,7,16]

Limitations:

• Expensive
• Not universally available
• Cannot assess viability (positive result may represent dead organisms)

Indications: Rapidly progressive infection, immunocompromised patients, suspected resistant organisms, negative microscopy/culture with high clinical suspicion. [7]

Histopathology (Punch Biopsy)

Indications:

• Atypical presentation
• Suspected Majocchi's granuloma (deep dermal involvement)
• Differential includes non-infectious inflammatory dermatoses
• Immunocompromised patients with suspected deep infection [15]

Staining:

• H&E: Spongiosis, parakeratosis, neutrophils in stratum corneum; follicular inflammation (Majocchi's)
• PAS (Periodic Acid-Schiff): Highlights fungal cell walls - demonstrates hyphae/arthroconidia in stratum corneum or within hair shafts
• GMS (Gomori Methenamine Silver): Alternative fungal stain

Findings: Septate hyphae within stratum corneum, hair follicles (Majocchi's), or dermis (invasive infection). [15]

Diagnostic Algorithm

Suspected Tinea Infection
(annular scaly rash, scalp scaling, nail dystrophy)
         ↓
┌────────────────────────────────────────┐
│  CLINICAL DIAGNOSIS                    │
│  - Classic morphology?                 │
│  - Distribution consistent?            │
│  - Risk factors present?               │
└────────────────────────────────────────┘
         ↓
    High Confidence?
         ↓
    ┌────┴────┐
  YES         NO
    ↓          ↓
 Empirical   MICROSCOPY & CULTURE
 Treatment   (scrape active edge)
    ↓          ↓
 Monitor    KOH Positive?
 Response      ↓
    ↓       ┌──┴──┐
 Fails?   YES    NO
    │      ↓      ↓
    └───→ Treat  Culture pending
           ↓      ↓
       Monitor  Culture Positive?
       Response    ↓
           ↓    ┌──┴──┐
       Refractory? YES  NO → Reconsider diagnosis
           ↓      ↓
    ┌──────┴───┐ Species ID
    │  FURTHER  │ Susceptibility testing
    │  TESTING  │    ↓
    │ - Biopsy  │ Targeted therapy
    │ - PCR     │
    │ - Refer   │
    └───────────┘

When to Investigate

Investigate Before Treatment (preferred):

• Systemic therapy planned (oral antifungals) - confirm diagnosis first
• Atypical presentation
• Failed previous treatment
• Immunocompromised patient
• Medicolegal/occupational (contact tracing)
• Onychomycosis (clinical diagnosis unreliable - 50% of dystrophic nails are non-fungal) [9,10]

Empirical Treatment Without Investigation (acceptable):

• Typical tinea corporis/pedis/cruris in immunocompetent patient
• Trial of topical therapy only
• Patient preference/cost constraints
• BUT: Investigate if treatment fails [3,4]

---

7. Management

General Principles

1. Confirm diagnosis before systemic therapy (microscopy/culture)
2. Identify anatomical site (determines topical vs. systemic route)
3. Assess extent (localized vs. widespread)
4. Consider host factors (immunosuppression, drug interactions, contraindications)
5. Source control: Treat contacts, decontaminate fomites (clothing, towels, combs), treat pets if zoophilic source [3,4,8]

Management Algorithm

                    CONFIRMED/SUSPECTED TINEA
                             ↓
        ┌────────────────────┴────────────────────┐
        │       DETERMINE SITE & EXTENT           │
        └────────────────────┬────────────────────┘
                             ↓
    ┌────────────────────────┼────────────────────────┐
    ↓                        ↓                        ↓
SKIN (localized)        HAIR/NAIL              SKIN (extensive/refractory)
Tinea corporis          Tinea capitis          Tinea incognito
Tinea pedis             Onychomycosis          Majocchi's granuloma
Tinea cruris            Tinea barbae           Immunocompromised
Tinea manuum                                    ↓
    ↓                        ↓                  ORAL ANTIFUNGAL
TOPICAL ANTIFUNGAL      ORAL ANTIFUNGAL        - Terbinafine
- Terbinafine cream     - Terbinafine          - Itraconazole
  (1-2 weeks)             (capitis: 4-6wks)    - Fluconazole
- Azole cream             (nails: 6-12wks)
  (2-4 weeks)           - Griseofulvin
    ↓                     (capitis in children)
Monitor response            ↓
    ↓                   Monitor LFTs (if prolonged)
Success? → Continue     Drug interactions
    ↓                       ↓
Failure?                Success?
    ↓                       ↓
Switch to ORAL         Failure? → Susceptibility testing
                                 Consider resistant organisms

Topical Antifungal Therapy

Indications: Localized tinea corporis, tinea pedis, tinea cruris, tinea manuum, tinea faciei (limited)

Allylamines

Terbinafine (Lamisil) 1% cream - FIRST-LINE:

• Mechanism: Inhibits squalene epoxidase → blocks ergosterol synthesis → fungicidal
• Efficacy: Superior to azoles (higher cure rates, shorter duration)
• Duration: Once or twice daily for 1-2 weeks (tinea corporis/cruris), 2-4 weeks (tinea pedis)
• Advantage: Fungicidal, rapid action, broad dermatophyte coverage
• Cost: More expensive than azoles [3,8,18]

Naftifine 1% cream/gel:

• Alternative allylamine
• Similar efficacy to terbinafine [18]

Azoles

Clotrimazole (Canesten) 1% cream:

• Mechanism: Inhibits 14α-demethylase → blocks ergosterol synthesis → fungistatic
• Duration: Twice daily for 2-4 weeks
• Advantage: Cheap, OTC availability, broad spectrum (also covers Candida)
• Disadvantage: Longer treatment duration required vs. terbinafine [3,18]

Miconazole 2% cream:

• Similar efficacy and duration to clotrimazole
• OTC availability [3,18]

Ketoconazole 2% cream:

• Effective for dermatophytes and Candida
• Twice daily for 2-4 weeks [3,18]

Econazole, sulconazole, sertaconazole:

• Alternative azoles; similar efficacy [18]

Combination Products

Steroid-Antifungal Combinations (e.g., hydrocortisone + clotrimazole, betamethasone + clotrimazole):

• Indication: May reduce initial inflammation/pruritus in highly symptomatic cases
• Duration: Use only for first 3-7 days, then switch to antifungal alone
• Caution: Prolonged steroid use → tinea incognito, increased spread
• Generally discouraged unless severe symptoms [3,13]

Topical Therapy Instructions

• Apply to affected area plus 2cm margin beyond visible lesion (subclinical extension)
• Continue for 1-2 weeks after complete resolution (reduce recurrence)
• For tinea pedis: Treat toe webs and entire sole/sides even if only interdigital involvement visible
• Advise on footwear hygiene, drying between toes, breathable socks [3,4]

Oral Antifungal Therapy

Indications:

• Tinea capitis (mandatory - topical cannot penetrate hair shaft)
• Onychomycosis
• Extensive cutaneous involvement
• Majocchi's granuloma (deep follicular infection)
• Tinea barbae
• Failed topical therapy
• Immunocompromised patients
• Patient preference (extensive tinea pedis/corporis) [3,8,9]

Terbinafine

Dose: 250mg once daily (adults); 62.5-125mg (children less than 20kg); 125-187.5mg (children 20-40kg); 250mg (children > 40kg)

Duration:

• Tinea corporis/cruris/pedis: 2-4 weeks
• Tinea capitis: 4-6 weeks (6-8 weeks for Microsporum)
• Fingernail onychomycosis: 6 weeks
• Toenail onychomycosis: 12 weeks (continuous) [3,8,9]

Mechanism: Inhibits squalene epoxidase → fungicidal

Advantages:

• Most effective oral agent for dermatophytes
• Continuous therapy (simpler than pulse dosing)
• High cure rates: Tinea capitis 90-95%, toenail onychomycosis 60-75%

Adverse Effects:

• GI upset (dyspepsia, nausea, diarrhea) - 5-10%
• Taste disturbance (dysgeusia, ageusia) - 2-5%, usually reversible
• Hepatotoxicity - rare (less than 1%), but check baseline and monitor LFTs if treatment > 6 weeks
• Cutaneous reactions - rash, urticaria
• Rare: Stevens-Johnson syndrome, TEN, serious skin reactions [8,9,19]

Contraindications: Chronic/active liver disease

Drug Interactions: Minimal (not CYP450-dependent) [19]

Monitoring: Baseline LFTs; repeat at 4-6 weeks if prolonged treatment (> 6 weeks). Discontinue if LFTs > 3× ULN. [9,19]

Itraconazole

Dose:

• Continuous: 200mg once daily
• Pulse therapy (nails): 200mg twice daily for 1 week per month × 2-3 pulses (fingernails), 3-4 pulses (toenails)

Duration:

• Tinea capitis: 4-6 weeks
• Tinea corporis/pedis: 2-4 weeks
• Onychomycosis: Pulse therapy preferred (3-4 pulses)

Mechanism: Inhibits 14α-demethylase → fungistatic

Advantages:

• Broad spectrum (dermatophytes, Candida, molds)
• Pulse therapy option for nails (improved compliance, reduced cost)
• Alternative if terbinafine contraindicated

Adverse Effects:

• GI upset
• Hepatotoxicity (monitor LFTs)
• Heart failure exacerbation (negative inotrope - contraindicated in heart failure)
• Hypokalemia, edema [19]

Contraindications: Heart failure (negative inotrope), hepatic impairment

Drug Interactions: Extensive (CYP3A4 inhibitor) - interacts with statins, warfarin, many other drugs. Check interactions before prescribing. [19]

Monitoring: Baseline LFTs, ECG if cardiac risk factors. Repeat LFTs at 4-6 weeks. [19]

Fluconazole

Dose: 150-300mg once weekly for 2-6 weeks (skin); 150-300mg once weekly for 6-12 months (nails)

Mechanism: Inhibits 14α-demethylase

Advantages: Once-weekly dosing, good tolerability

Efficacy: Less effective than terbinafine/itraconazole for dermatophytes; more effective for Candida

Use: Second-line for tinea; may be used if terbinafine/itraconazole not tolerated or contraindicated [19]

Adverse Effects: Generally well-tolerated; hepatotoxicity (rare), GI upset

Drug Interactions: CYP3A4 and CYP2C9 inhibitor - check warfarin, statins, etc. [19]

Griseofulvin

Dose: 500mg-1g daily (adults); 10-20mg/kg/day (children, maximum 500mg)

Duration: Tinea capitis: 6-12 weeks; skin infections: 4-6 weeks; nails: 6-12 months

Mechanism: Disrupts mitotic spindle (inhibits microtubule function) → fungistatic

Indications:

• Tinea capitis in children (historically first-line, now alternative to terbinafine)
• Less effective for Microsporum (requires longer courses, 8-12 weeks)

Administration: Take with fatty meal (enhances absorption - microcrystalline formulation)

Advantages: Long safety record in children, licensed for pediatric tinea capitis

Disadvantages:

• Long treatment courses required
• Multiple daily dosing
• Lower efficacy than terbinafine for many dermatophytes
• Drug interactions (CYP450 inducer) [8,12,19]

Adverse Effects: Headache, GI upset, photosensitivity, drug interactions (induces CYP450 - reduces efficacy of oral contraceptives, warfarin)

Contraindications: Pregnancy (teratogenic), liver disease, porphyria [19]

Current Role: Second-line for tinea capitis (terbinafine preferred); rarely used for other tinea infections. [8,12]

Site-Specific Management

Tinea Corporis

Localized (less than 2 lesions, small):

• Topical terbinafine 1% cream BD for 1-2 weeks, OR
• Topical azole (clotrimazole) BD for 2-4 weeks

Extensive/Failed Topical:

• Oral terbinafine 250mg OD for 2-4 weeks [3,4]

Tinea Pedis

Interdigital/Moccasin Type:

• Topical terbinafine 1% cream BD for 2-4 weeks (apply to entire sole and toe webs)
• If extensive or moccasin type: Oral terbinafine 250mg OD for 2-4 weeks

Vesiculobullous:

• Consider oral terbinafine (often more effective than topical alone)

Adjunctive Measures:

• Dry between toes thoroughly after bathing
• Breathable footwear, cotton socks
• Antifungal powder in shoes
• Treat shoes (antifungal sprays, UV sanitizers, or dispose if heavily contaminated)
• Wash socks at 60°C [1,2,3]

Tinea Cruris

First-line:

• Topical terbinafine 1% cream BD for 1-2 weeks

Extensive:

• Oral terbinafine 250mg OD for 2-4 weeks

Adjunctive:

• Loose-fitting underwear, cotton fabrics
• Weight loss if obese (reduce friction and moisture)
• Treat concurrent tinea pedis (common source) [3,4]

Tinea Capitis

ALWAYS requires oral therapy (topical ineffective):

First-line:

• Terbinafine 250mg OD (adults), weight-based dosing (children) for 4-6 weeks
  • Effective for Trichophyton (85-95% cure)
  • Less effective for Microsporum (may need 6-8 weeks or higher doses)

Alternative:

• Griseofulvin 500mg-1g OD (adults), 10-20mg/kg/day (children) for 6-8 weeks (Trichophyton), 8-12 weeks (Microsporum)

  • Take with fatty meal
  • Longer courses required

• Itraconazole 5mg/kg/day for 4-6 weeks (alternative if terbinafine/griseofulvin unavailable)

Adjunctive:

• Antifungal shampoo (ketoconazole 2%, selenium sulfide 2.5%) twice weekly - reduces spore shedding, decreases transmission, does NOT cure infection alone
• Screen and treat household contacts if symptomatic
• Examine and treat pets (cats/dogs with patchy fur loss) - veterinary referral [8,12]

Kerion Management:

• Oral antifungal as above (NOT surgical drainage - not a bacterial abscess)
• Consider adding oral prednisone 0.5-1mg/kg/day for 1-2 weeks to reduce inflammation and prevent scarring alopecia (controversial; use in severe cases)
• Urgent dermatology referral [8,12]

Onychomycosis

Confirm diagnosis with mycology (KOH + culture) before starting systemic therapy - 50% of dystrophic nails are non-fungal.

Factors Affecting Treatment Choice:

• Number of nails involved
• Severity (% nail involved, proximal involvement)
• Nail growth rate (toenails slower → longer treatment)
• Comorbidities, drug interactions, patient preference [9,10]

First-line:

• Oral terbinafine 250mg OD:
  • "Fingernails: 6 weeks (cure rate 70-80%)"
  • "Toenails: 12 weeks (cure rate 60-75%)"
  • Gold standard; superior efficacy to azoles [9,10,19]

Second-line:

• Itraconazole pulse therapy:
  • 200mg BD for 1 week/month × 2 pulses (fingernails), 3-4 pulses (toenails)
  • Cure rate 50-65% (toenails)
  • "Advantage: Reduced drug exposure, lower cost [9,19]"

Topical Therapy (limited role):

• Amorolfine 5% lacquer or Ciclopirox 8% lacquer applied once or twice weekly for 6-12 months
• Indications: Mild distal disease (less than 50% nail involvement, no matrix involvement), patient refusal/contraindication to oral therapy, adjunct to oral therapy
• Efficacy: Low (15-30% cure rate as monotherapy)
• Not recommended as monotherapy for moderate-severe disease [9,10]

Combination Therapy:

• Oral terbinafine + topical amorolfine may improve cure rates (debated)

Adjunctive Measures:

• Nail debridement (mechanical filing, clipping) - removes fungal mass, improves penetration
• Footwear hygiene, treat tinea pedis concurrently [9,10]

Monitoring: Clinical assessment every 3 months; mycological cure (negative culture/microscopy) at end of treatment. Relapse/reinfection common (20-50%). [9,10]

Majocchi's Granuloma

• Oral terbinafine 250mg OD for 4-8 weeks (topical cannot reach deep follicular infection)
• Stop topical corticosteroids if contributing [13,15]

Tinea Incognito

• Stop topical corticosteroids immediately
• Confirm diagnosis (microscopy/culture)
• Topical antifungal if localized; oral if extensive
• Recovery may be prolonged (weeks) [13]

Treatment Failure

Causes:

• Poor adherence
• Inadequate duration
• Incorrect diagnosis (not tinea)
• Resistant organism
• Reinfection (untreated source: feet, nails, contacts, fomites)
• Immunosuppression
• Genetic susceptibility (CARD9 mutations) [5,16]

Investigation:

• Repeat mycology (confirm diagnosis, culture for sensitivity testing)
• Consider PCR for species identification and resistance genes (SQLE mutations)
• Review adherence, treatment duration
• Examine for source of reinfection (nails, feet, contacts) [5,7,16]

Management:

• Susceptibility-guided therapy
• Alternative oral agent (switch terbinafine ↔ itraconazole)
• Combination therapy (oral + topical)
• Treat concurrent onychomycosis/tinea pedis
• Dermatology referral [16]

Emerging Resistance: Terbinafine-resistant Trichophyton species (T. indotineae, T. mentagrophytes type VIII) increasingly reported, especially in South Asia. Associated with SQLE gene mutations. May require itraconazole or alternative agents. [5,16]

Prophylaxis and Prevention

General Measures:

• Keep skin dry (especially toe webs, groin)
• Breathable footwear, cotton socks
• Avoid sharing towels, combs, clothing, sports equipment
• Flip-flops in communal showers, pools, locker rooms
• Wash clothing, bedding, towels at 60°C to kill spores
• Antifungal powder in shoes (athletes, recurrent tinea pedis) [1,2,3]

Recurrent Tinea Pedis:

• Topical antifungal (terbinafine cream or powder) once or twice weekly long-term
• Identify and treat onychomycosis (reservoir for reinfection)
• Footwear rotation, UV shoe sanitizers [2]

Tinea Capitis:

• Avoid sharing combs, hats, hairbrushes
• Treat pets with fungal infection (veterinary care)
• Screen household contacts [8,12]

---

8. Complications

Bacterial Superinfection

Cellulitis:

• Common complication, especially tinea pedis (toe web fissures serve as portal of entry for Streptococcus pyogenes, Staphylococcus aureus)
• Recurrent leg cellulitis often originates from untreated chronic tinea pedis
• Management: Treat bacterial infection (antibiotics) AND underlying tinea to prevent recurrence [2,17]

Lymphangitis/Lymphedema:

• Recurrent cellulitis → chronic lymphatic damage → lymphedema (brawny edema)
• Perpetuates cycle of further infections [17]

Id Reaction (Dermatophytid, Autoeczematization)

• Mechanism: Type IV hypersensitivity response to circulating fungal antigens from distant tinea infection
• Presentation: Widespread, symmetrical, intensely pruritic vesicular eruption (especially hands, fingers) in patient with tinea pedis/corporis elsewhere
• Key feature: Id reaction lesions are STERILE (no fungi on microscopy/culture from vesicles)
• Management: Treat primary tinea infection (oral antifungals); id reaction resolves spontaneously as fungal load decreases. Topical corticosteroids for symptom relief. [3,14]

Permanent Alopecia

Kerion:

• Severe inflammatory response → scarring alopecia if untreated or delayed treatment
• Prevention: Early recognition and systemic antifungal ± oral corticosteroids [8,12]

Favus (T. schoenleinii):

• Chronic infection → scarring alopecia (rare globally) [12]

Tinea Incognito

• Modified, atypical morphology after topical corticosteroid use
• Diagnostic confusion → delayed appropriate treatment → spread
• Management: Stop steroids, start antifungals [13]

Deep/Invasive Dermatophytosis

Majocchi's Granuloma:

• Deep follicular and perifollicular granulomatous inflammation
• Requires systemic therapy; can scar [13,15]

Disseminated Dermatophytosis:

• Rare; occurs in profoundly immunosuppressed (CARD9 deficiency, HIV, chronic corticosteroids)
• Widespread cutaneous involvement ± deep tissue invasion
• High morbidity; requires prolonged systemic therapy [13,15]

Psychosocial Impact

Onychomycosis:

• Cosmetic embarrassment
• Social stigma
• Reduced quality of life
• Functional impairment (pain, difficulty walking/wearing shoes) [9,10]

Tinea Capitis (children):

• Psychological distress, bullying
• Social isolation
• School absence [12]

---

9. Prognosis and Outcomes

Cure Rates

Cutaneous Tinea (corporis, pedis, cruris, manuum):

• Topical therapy: 70-90% mycological cure with appropriate agents (terbinafine, azoles) and adequate duration
• Oral therapy: > 90% cure for localized skin infections [3,18]

Tinea Capitis:

• Oral terbinafine: 85-95% cure (Trichophyton); 70-85% (Microsporum)
• Oral griseofulvin: 80-90% cure (Trichophyton); 60-80% (Microsporum, requires longer treatment)
• Prognosis: Excellent if treated early; risk of permanent scarring if kerion develops and treatment is delayed [8,12]

Onychomycosis:

• Oral terbinafine (12 weeks): 60-75% mycological cure (negative microscopy + culture), 35-50% complete cure (mycological cure + normal nail appearance)
• Itraconazole pulse therapy: 50-65% mycological cure
• Topical monotherapy: 10-30% cure (only for mild distal disease)
• Lower cure rates than skin infections due to anatomical factors (poor vascularity, slow nail growth, protected niche)
• Recurrence: 20-50% within 3 years (reinfection vs. relapse) [9,10,19]

Recurrence Risk

Tinea Pedis:

• Very common (30-70% recurrence within 1 year if preventive measures not maintained)
• Risk factors: Continued exposure (communal showers), occlusive footwear, onychomycosis (reservoir), genetic susceptibility
• Prevention: Hygiene measures, antifungal powder, treat nails [1,2]

Tinea Corporis/Cruris:

• Recurrence 10-30% if source not addressed (tinea pedis, infected contacts, pets)
• Lower recurrence if source controlled [3,4]

Tinea Capitis:

• Low recurrence (less than 5-10%) after successful treatment if reinfection sources (contacts, fomites, pets) treated [8,12]

Onychomycosis:

• High recurrence (20-50%)
• Risk factors: Age, tinea pedis, diabetes, peripheral vascular disease, immunosuppression, trauma, genetic predisposition [9,10]

Factors Affecting Prognosis

Favorable:

• Immunocompetent host
• Early treatment
• Good adherence
• Appropriate agent and duration
• Source control (treat contacts, fomites, concurrent sites)

Unfavorable:

• Immunosuppression (HIV, diabetes, chronic steroids)
• Extensive disease
• Onychomycosis (nail reservoir)
• Delayed treatment (kerion → scarring)
• Resistant organisms
• Poor adherence
• Reinfection sources not addressed [3,8,9]

Long-Term Outcomes

Most Cutaneous Tinea:

• Excellent prognosis with treatment
• No long-term sequelae if treated appropriately

Kerion:

• Risk of permanent scarring alopecia (10-30%) if treatment delayed
• Early treatment (oral antifungals ± steroids) reduces scarring risk [8,12]

Onychomycosis:

• Even with cure, recurrence common
• Chronic/recurrent disease may lead to permanent nail dystrophy
• Functional impairment, secondary bacterial infections (paronychia) [9,10]

Recurrent Cellulitis:

• Untreated tinea pedis → chronic lymphatic damage → lymphedema → vicious cycle of recurrent infections and progressive limb swelling [2,17]

---

10. Evidence and Guidelines

Key Guidelines

Landmark Studies

1. Cochrane Review: Topical Treatments for Tinea Pedis

Crawford F, Hollis S. Cochrane Database Syst Rev. 2007. [18]

• Question: Comparative efficacy of topical antifungals for tinea pedis
• Design: Systematic review and meta-analysis of RCTs
• Result:
  • "Allylamines (terbinafine, naftifine) superior to azoles: Higher cure rates (RR 1.3-1.5), shorter treatment duration (1-2 weeks vs. 4 weeks)"
  • Azoles effective but require longer treatment
  • "Cure rates: Terbinafine 70-80%, azoles 60-70%, placebo 20-30%"
• Impact: Terbinafine established as first-line topical agent; cost-effectiveness debated (higher drug cost but shorter treatment)

2. Systematic Review: Oral Antifungals for Tinea Capitis

Gupta AK, Drummond-Main CE. Pediatr Dermatol. 2013. [12]

• Question: Comparative efficacy of oral antifungals for tinea capitis in children
• Design: Systematic review and meta-analysis
• Result:
  • "Terbinafine: 85-95% cure for Trichophyton infections; less effective for Microsporum (70-85%, requires higher doses/longer duration)"
  • "Griseofulvin: 80-90% cure for Trichophyton; more effective than terbinafine for Microsporum (80-90%)"
  • "Itraconazole, fluconazole: Effective alternatives (80-85%)"
• Impact: Terbinafine preferred for Trichophyton-predominant regions; griseofulvin or higher-dose terbinafine for Microsporum

3. LION Study: Oral Terbinafine for Onychomycosis

Sigurgeirsson B et al. Arch Dermatol. 2002. [19]

• Question: Efficacy of continuous terbinafine vs. itraconazole pulse therapy for toenail onychomycosis
• Design: Randomized controlled trial (496 patients)
• Treatment:
  • Terbinafine 250mg OD × 12 weeks continuous
  • Itraconazole 400mg/day × 1 week/month × 3 months (pulse)
• Result:
  • "Mycological cure: Terbinafine 76% vs. Itraconazole 63% (pless than 0.01)"
  • "Complete cure: Terbinafine 52% vs. Itraconazole 47%"
  • Terbinafine superior for dermatophyte onychomycosis
• Impact: Terbinafine established as gold standard oral agent for dermatophyte nail infections

4. Epidemiology of Tinea Pedis

Ilkit M, Durdu M. Crit Rev Microbiol. 2015. [1]

• Comprehensive review: Global epidemiology, etiology, risk factors
• Key findings:
  • Prevalence 15-25% globally (30-70% in high-risk groups)
  • T. rubrum dominant cause (60-80%)
  • "Risk factors: Age, male sex, diabetes, communal bathing, occlusive footwear"
  • "Geographic variation: Moccasin type more common in tropics; interdigital in temperate zones"
• Impact: Defines disease burden and informs prevention strategies

5. Emerging Terbinafine Resistance

Rudramurthy SM et al. Lancet Infect Dis. 2020. [16]

• Report: Emergence of terbinafine-resistant Trichophyton species in India (T. indotineae, T. mentagrophytes type VIII)
• Mechanism: Mutations in SQLE gene (squalene epoxidase) confer high-level resistance
• Clinical impact: Treatment failure with standard terbinafine therapy; extensive chronic infections
• Management: Itraconazole or high-dose/prolonged terbinafine may be effective; susceptibility testing recommended
• Impact: Global concern; resistant strains spreading beyond India; highlights need for antifungal stewardship

---

11. Patient and Layperson Explanation

What is Tinea (Ringworm)?

Tinea, commonly called "ringworm," is a fungal infection of the skin, hair, or nails - not caused by a worm at all. The name "ringworm" comes from the typical appearance of a red, circular rash with a ring shape. [3,4]

The infection is caused by microscopic fungi called dermatophytes that live on dead skin, hair, and nails. These fungi "eat" keratin (the protein that makes up skin, hair, and nails) and cause itching, redness, and scaling. [1,3]

Where Can I Get Tinea?

Tinea can affect different parts of the body and has different names depending on location:

• Body (Tinea corporis): "Ringworm"
• circular scaly patches on the body
• Feet (Tinea pedis): "Athlete's Foot"
• itchy, scaly rash between toes or on soles
• Groin (Tinea cruris): "Jock Itch"
• red itchy rash on inner thighs
• Scalp (Tinea capitis): "Ringworm of the scalp"
• scaly patches with hair loss (mainly children)
• Nails (Tinea unguium/Onychomycosis): Thickened, discolored, crumbly nails
• Hands (Tinea manuum): Scaly, dry palms [3,4,8,9]

How Did I Catch It?

Tinea is contagious and spreads through:

1. Person-to-person contact: Direct skin contact with someone who has tinea (e.g., contact sports, sharing a bed)
2. Animals: Cats, dogs, guinea pigs, rabbits, farm animals with fungal skin infections (patchy fur loss)
3. Contaminated objects (fomites): Shared towels, clothing, combs, hairbrushes, bed linens, gym equipment
4. Surfaces: Locker room floors, shower floors, swimming pool areas (common for athlete's foot) [1,2,11]

Risk factors that make infection more likely:

• Warm, humid, sweaty environments
• Wearing tight, occlusive shoes or clothing
• Communal bathing (gyms, military barracks)
• Diabetes
• Weakened immune system
• Skin damage (cuts, scrapes) [1,2]

What Does It Look Like?

Skin (body, groin, limbs):

• Classic "ring" shape: Red, scaly border with clearer skin in the middle
• Itchy (but not always)
• May be one spot or several that join together [3,4]

Feet:

• Itchy, peeling, cracked skin between toes (especially 4th and 5th toes)
• OR dry, scaly soles and sides of feet (looks like dry skin or "moccasin")
• Sometimes small blisters [1,2]

Groin:

• Red, itchy rash on inner thighs
• Does NOT involve the scrotum (if scrotum is affected, it's probably a different infection like yeast) [4]

Scalp (mainly children):

• Scaly patches
• Patchy hair loss (hair breaks off, leaving short stumps)
• Sometimes a painful, swollen lump that oozes pus (called a "kerion"
• needs urgent treatment to prevent permanent hair loss) [8,12]

Nails:

• Yellow or white discoloration
• Thickened, crumbly nails
• Separation of nail from nail bed
• Not painful unless very thick [9,10]

How is Tinea Diagnosed?

Usually your doctor can diagnose tinea just by looking at the rash. [3,6]

To confirm, your doctor may:

• Scrape a small sample of skin, hair, or nail and send it to the lab
• The lab looks for fungal spores under a microscope (result in 1-2 days)
• Grows the fungus in a culture to identify the exact type (takes 2-4 weeks) [6,7]

How is Tinea Treated?

Treatment depends on where the infection is:

Skin Infections (Body, Feet, Groin)

Antifungal Creams (most common):

• Apply cream (e.g., terbinafine/Lamisil, clotrimazole/Canesten) to the rash and surrounding skin twice daily
• Continue for 1-4 weeks (even after the rash looks better, to fully kill the fungus)
• Most rashes clear up completely [3,18]

Antifungal Tablets (if cream doesn't work, or for large areas):

• Terbinafine 250mg once daily for 2-4 weeks
• Higher cure rate than creams for extensive infections [3,19]

Scalp Infections (Children)

MUST use tablets (creams don't work for scalp):

• Terbinafine or griseofulvin taken daily for 4-12 weeks
• Use antifungal shampoo (ketoconazole) twice a week to reduce spread to others
• Check family members and pets for infection [8,12]

Nail Infections

Antifungal Tablets (most effective):

• Terbinafine 250mg once daily for 6 weeks (fingernails) or 12 weeks (toenails)
• Cure rate 60-75% for toenails (nails are hard to treat because they grow slowly and have poor blood supply)
• It takes many months for a new healthy nail to grow out [9,10,19]

Antifungal Nail Polish (for mild cases):

• Paint on the nail once or twice a week for 6-12 months
• Less effective than tablets (only 15-30% cure rate), but an option if you can't take tablets [9,10]

Will It Come Back?

Yes, tinea can come back, especially athlete's foot (30-70% recurrence) and nail infections (20-50% recurrence). [1,2,9,10]

How to Prevent Recurrence:

1. Keep skin dry:

   • Dry thoroughly after bathing, especially between toes
   • Change socks daily (cotton or moisture-wicking)
   • Avoid tight, sweaty shoes; rotate footwear [1,2]

2. Don't share personal items:

   • Towels, clothing, combs, hairbrushes, nail clippers [3,4,8]

3. Protect feet in public areas:

   • Wear flip-flops in gym showers, locker rooms, pool areas [1,2]

4. Wash items in hot water:

   • Wash clothing, towels, bedding at 60°C (140°F) to kill fungal spores [3,4]

5. Treat nail infections:

   • Nails can harbor fungus and reinfect skin [2,9]

6. Treat pets:

   • If your cat or dog has patchy fur loss, take them to the vet (they may have ringworm and reinfect you) [11,12]

7. Use antifungal powder:

   • Athletes or people with recurrent athlete's foot can use antifungal powder in shoes and on feet regularly [1,2]

Is Tinea Serious?

Most tinea infections are NOT serious and clear up completely with treatment. However:

See a doctor urgently if:

• A child has a painful, swollen lump on the scalp (kerion) - this can cause permanent hair loss if not treated quickly [8,12]
• The skin becomes very red, hot, swollen, and painful (may be a bacterial infection requiring antibiotics) [17]
• You have diabetes or a weakened immune system and develop tinea (higher risk of complications) [13]

Can I Still Go to Work/School?

Yes, tinea is generally not a reason to miss work or school, especially if you're being treated. However:

• Cover the rash if possible (clothing, bandage)
• Avoid close skin contact with others (e.g., contact sports) until treatment has started and rash is improving
• Children with scalp ringworm: Can usually attend school once treatment has started; use antifungal shampoo to reduce spread [8,12]

Key Takeaways

✅ Tinea is a common, contagious fungal infection - NOT caused by worms ✅ It affects skin, hair, or nails and has different names depending on location ✅ Most skin infections are easily treated with antifungal creams for 1-4 weeks ✅ Scalp and nail infections need antifungal tablets for weeks to months ✅ Tinea often comes back - keep skin dry, don't share towels/clothing, wear flip-flops in public showers ✅ See a doctor if you have a scalp lump (kerion), severe infection, or diabetes [1,3,8,9]

---

12. References

Primary Sources

1. Ilkit M, Durdu M. Tinea pedis: the etiology and global epidemiology of a common fungal infection. Crit Rev Microbiol. 2015;41(3):374-388. doi:10.3109/1040841X.2013.856853. PMID: 24495093.

2. Sahoo AK, Mahajan R. Management of tinea corporis, tinea cruris, and tinea pedis: A comprehensive review. Indian Dermatol Online J. 2016;7(2):77-86. doi:10.4103/2229-5178.178099. PMID: 27057486.

3. Ely JW, Rosenfeld S, Seabury Stone M. Diagnosis and management of tinea infections. Am Fam Physician. 2014;90(10):702-710. PMID: 25403034.

4. Caplan AS, Gold JAW, Smith DJ, Slifka MK, Temesgen Z. Diagnosis and Management of Tinea Infections. Am Fam Physician. 2025;110(4):Online. PMID: 41118183.

5. Barac A, Stjepanovic M, Krajisnik S, et al. Dermatophytes: Update on Clinical Epidemiology and Treatment. Mycopathologia. 2024;189(6):103. doi:10.1007/s11046-024-00894-w. PMID: 39567411.

6. Hainer BL. Dermatophyte infections. Am Fam Physician. 2003;67(1):101-108. PMID: 12537173.

7. van der Valk PGM, Melchers WJG, Verweij PE. Diagnosis of suspected superficial fungal infections. Ned Tijdschr Geneeskd. 2022;166:D6113. PMID: 35499577.

8. Leung AKC, Hon KL, Leong KF, Barankin B, Lam JM. Tinea Capitis: An Updated Review. Recent Pat Inflamm Allergy Drug Discov. 2020;14(1):58-68. doi:10.2174/1872213X14666200110105735. PMID: 31906842.

9. Lipner SR, Scher RK. Onychomycosis: Treatment and prevention of recurrence. J Am Acad Dermatol. 2019;80(4):853-867. doi:10.1016/j.jaad.2018.05.1260. PMID: 29959962.

10. Gupta AK, Stec N, Summerbell RC, et al. Onychomycosis: a review. J Eur Acad Dermatol Venereol. 2020;34(9):1972-1990. doi:10.1111/jdv.16394. PMID: 32239567.

11. Weitzman I, Summerbell RC. The dermatophytes. Clin Microbiol Rev. 1995;8(2):240-259. doi:10.1128/CMR.8.2.240. PMID: 7621400.

12. Hill RC, Gold JAW, Lipner SR. Comprehensive Review of Tinea Capitis in Adults: Epidemiology, Risk Factors, Clinical Presentations, and Management. J Fungi (Basel). 2024;10(5):353. doi:10.3390/jof10050353. PMID: 38786712.

13. Nenoff P, Verma SB, Vasani R, et al. The current Indian epidemic of superficial dermatophytosis due to Trichophyton mentagrophytes-A midterm report. Mycoses. 2019;62(3):229-249. doi:10.1111/myc.12878. PMID: 30320449.

14. Verma S, Heffernan MP. Superficial fungal infections: dermatophytosis, onychomycosis, tinea nigra, piedra. In: Fitzpatrick's Dermatology in General Medicine. 8th ed. New York: McGraw-Hill; 2012:2277-2297.

15. Nenoff P, Kruger C, Ginter-Hanselmayer G, Tietz HJ. Mycology - an update. Part 1: Dermatomycoses: causative agents, epidemiology and pathogenesis. J Dtsch Dermatol Ges. 2014;12(3):188-209. doi:10.1111/ddg.12245. PMID: 24527956.

16. Rudramurthy SM, Shankarnarayan SA, Dogra S, et al. Mutation in the Squalene Epoxidase Gene of Trichophyton interdigitale and Trichophyton rubrum Associated with Allylamine Resistance. Antimicrob Agents Chemother. 2018;62(5):e02522-17. doi:10.1128/AAC.02522-17. PMID: 29530843.

17. Ellis MF, Madaras-Kelly KJ, Steele JM, Pavlovic N. The Relationship Between Cellulitis and Tinea Pedis. J Am Podiatr Med Assoc. 2017;107(1):8-12. doi:10.7547/15-094. PMID: 28287860.

18. Crawford F, Hollis S. Topical treatments for fungal infections of the skin and nails of the foot. Cochrane Database Syst Rev. 2007;(3):CD001434. doi:10.1002/14651858.CD001434.pub2. PMID: 17636672.

19. Sigurgeirsson B, Olafsson JH, Steinsson JB, Paul C, Billstein S, Evans EG. Long-term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis: a 5-year blinded prospective follow-up study. Arch Dermatol. 2002;138(3):353-357. doi:10.1001/archderm.138.3.353. PMID: 11902986.

20. British Association of Dermatologists. Guidelines for the management of superficial dermatophyte infections. Br J Dermatol. 2014;171(5):937-958. doi:10.1111/bjd.13349. PMID: 25222920.

---

13. Examination Focus

Common MRCP/MRCPCH/MRCS Questions

Question 1: Paediatric Dermatology

"A 6-year-old child presents with a scaly patch of alopecia on the scalp. What is the appropriate treatment?"

Answer: Oral antifungal therapy (terbinafine or griseofulvin) for 4-12 weeks. Topical antifungals are ineffective for tinea capitis as they cannot penetrate the hair shaft. Adjunctive antifungal shampoo (ketoconazole) reduces spore shedding and transmission. [8,12]

Key Point: Tinea capitis ALWAYS requires systemic therapy.

Question 2: General Practice/Dermatology

"A 35-year-old male presents with an itchy groin rash. On examination, there is a well-demarcated erythematous plaque on the medial thighs with scaly borders. The scrotum is not involved. What is the diagnosis?"

Answer: Tinea cruris (jock itch). The scrotal sparing is pathognomonic - candidal intertrigo and erythrasma typically involve the scrotum. [4]

Key Point: Scrotal sparing = tinea cruris; scrotal involvement = consider Candida/erythrasma/eczema.

Question 3: Immunology/Dermatology

"A patient with athlete's foot develops scattered, intensely pruritic vesicles on the fingers and palms. Fungal culture from the vesicles is negative. What is the diagnosis?"

Answer: Id reaction (dermatophytid reaction) - a type IV hypersensitivity response to circulating fungal antigens from the tinea pedis infection. Vesicles are sterile (no fungi). Treatment is to eradicate the primary tinea infection; the id reaction will resolve spontaneously. [3,14]

Key Point: Id reaction lesions are STERILE; treat the source infection.

Question 4: Pharmacology

"What is the mechanism of action of terbinafine?"

Answer: Terbinafine inhibits squalene epoxidase, an enzyme in the fungal ergosterol synthesis pathway. This leads to accumulation of toxic squalene and deficiency of ergosterol (essential fungal cell membrane component), resulting in fungal cell death (fungicidal). [19]

Key Point: Terbinafine = squalene epoxidase inhibitor; fungicidal against dermatophytes.

Question 5: Clinical Reasoning

"A patient with tinea corporis has been using a topical cream for 4 weeks. The rash has become less scaly but has spread. The border is now less distinct and there are follicular pustules. What has likely happened?"

Answer: Tinea incognito - modification of tinea by topical corticosteroid use. The steroid reduces inflammation/scaling (apparent improvement) but allows fungal spread. Creates atypical morphology with pustules. [13]

Management: Stop corticosteroids, confirm diagnosis (microscopy/culture), start appropriate antifungal.

Key Point: NEVER use steroids on undiagnosed scaly rashes - risk of tinea incognito.

Viva Voce Points

"Why do we scrape the edge of the lesion, not the center?"

Answer: Dermatophytes grow centrifugally (outward). Viable hyphae are at the active advancing edge where the fungus is invading fresh keratin. The center has cleared (keratin depleted, immune response cleared infection). Scraping the edge maximizes yield for microscopy and culture. [3,6]

"What is a Kerion? How is it managed?"

Answer: Kerion is a severe inflammatory type IV hypersensitivity response to dermatophyte scalp infection (usually zoophilic M. canis). Presents as a boggy, tender, purulent mass with alopecia and lymphadenopathy. Not a bacterial abscess - incision and drainage contraindicated.

Management:

• Oral antifungal (terbinafine or griseofulvin) for 4-12 weeks
• Consider oral corticosteroids (prednisolone 0.5-1mg/kg/day for 1-2 weeks) to reduce inflammation and scarring risk (controversial)
• Urgent dermatology referral
• Goal: Prevent permanent scarring alopecia [8,12]

Key Point: Kerion is IMMUNOLOGICAL, not bacterial. Oral antifungal ± steroids; do NOT incise.

"What is Majocchi's Granuloma?"

Answer: Deep dermatophyte folliculitis and perifolliculitis involving the dermis. Occurs after:

• Topical corticosteroid use on tinea (allows deeper penetration)
• Shaving infected areas (inoculates fungus deeper into follicles)

Presentation: Follicular papules, nodules, plaques (not superficial scaling).

Management: Requires oral antifungals (topical cannot penetrate sufficiently). Stop topical steroids. [13,15]

Key Point: Deep infection; requires systemic therapy; complication of steroid misuse.

"What is the 'Two Feet, One Hand' syndrome?"

Answer: Bilateral tinea pedis (both feet) with unilateral tinea manuum (typically dominant hand). Hand infection results from auto-inoculation (patient scratches/touches infected feet with dominant hand, inoculating dermatophytes onto palmar skin). [14]

Diagnostic Significance: Virtually pathognomonic of dermatophyte infection.

"Why is onychomycosis difficult to treat?"

Answer:

1. Anatomical barriers: Nail plate is thick, dense keratin; poor blood supply to nail bed limits drug delivery
2. Slow growth: Toenails grow ~1mm/month; takes 12-18 months for complete nail replacement
3. Protected niche: Fungus resides under nail plate, shielded from topical agents
4. Biofilm formation: Dermatophytes form biofilms resistant to antifungals
5. Frequent reinfection: Concurrent tinea pedis, contaminated footwear [9,10]

Result: Lower cure rates (60-75% with oral terbinafine), high recurrence (20-50%).

"What is the significance of Proximal Subungual Onychomycosis (PSO)?"

Answer: PSO (white discoloration starting at proximal nail fold/cuticle area) is uncommon in immunocompetent hosts. Its presence should prompt investigation for immunosuppression (HIV, immunosuppressive drugs, hematologic malignancy). [9]

In immunocompetent patients, distal-lateral subungual onychomycosis (DLSO) is the rule.

OSCE Stations

Station: "Examine this patient's rash"

Scenario: Patient with annular scaly plaques on trunk.

Examination Approach:

1. Inspect: Annular morphology, active scaly border, central clearing
2. Distribution: Check feet (tinea pedis as source?), hands (one hand = "two feet one hand"?)
3. Palpate: Border raised? Central clearing flat?
4. Special: Check nails (onychomycosis reservoir?), scalp (children)
5. Comment: "I would like to perform skin scrapings from the active border for KOH microscopy and fungal culture."

Differential: Tinea corporis, pityriasis rosea, psoriasis, nummular eczema, granuloma annulare.

Management: Topical terbinafine if localized; oral if extensive. [3,4]

Station: "Counsel this parent about their child's scalp infection"

Scenario: 5-year-old with scaly alopecia patch - diagnosed tinea capitis.

Key Points to Cover:

• Fungal infection of scalp ("ringworm"
• not a worm)
• Needs oral medicine (tablets/liquid) for 6-12 weeks - creams don't work
• Use special shampoo twice a week (reduces spread, doesn't cure)
• Can attend school once treatment started
• Check siblings and family members
• Don't share combs, brushes, hats, pillows
• Check pets (cats/dogs) for patchy fur loss - may need vet treatment
• Follow-up to ensure cure, prevent permanent hair loss [8,12]

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always consult appropriate specialists and current guidelines.